Genmab — Februar 2025
-
Genmab/Sydbank: Stærk prognose og flot bundlinje men option spøger stadig https://proinvestor.com/investornyt/1277752/genmab-sydbank-staerk-prognose-og-flot-bundlinje-men-option-spoger-stadig
-
Genmabs topchef om vigtig partnerafgørelse: Langsigtede investorer sidder på deres hænder https://proinvestor.com/investornyt/1277751/genmabs-topchef-om-vigtig-partnerafgorelse-langsigtede-investorer-sidder-pa-deres-haender
-
Genmab planlægger tilbagekøb af omkring 1,9 mio. egne aktier https://proinvestor.com/investornyt/1277750/genmab-planlaegger-tilbagekob-af-omkring-19-mio-egne-aktier
-
OVERBLIK: Disse selskaber er shortet på det danske aktiemarked https://proinvestor.com/investornyt/1277754/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked
-
Ifølge DB skulle det jo være godt for europæiske aktier https://danskebank.dk/privat/news/investeringsnyt/forside---investeringsnyt/2025/fred-i-ukraine-kan-genantaende-europaeiske-aktier?sc_cid=em|em|em-art-mar-InvesteringsnytW06b-em-2502|2
-
Novod løfter kursmålet til 2178, men fortsat hold "Genmab reported solid Q4 revenue of DKK 6,441m, up 38% y/y and 1% ahead of company-compiled consensus and our estimate. Q4 EBIT came in at DKK 2,160m, up 29% y/y and 7% ahead of consensus. For 2025, the company guides for revenue of DKK 24.05-26.35bn (midpoint: DKK 25.2bn) and EBIT of DKK 6.44-9.83bn (midpoint: DKK 8.14bn). Thus, we raise our 2025 top-line estimate by 2% and our EBIT estimate by 18%. We expect consensus estimate revisions of
-
~1-2% on the top line as well and 10-15% on EBIT. We finally see estimate revisions going in the right direction, but we stay on the sidelines, as we are still awaiting a high-risk decision from JnJ on Hexabody-CD38, which is still expected in Q1 2025. We maintain our Hold rating, with a higher DCF-derived fair value of DKK 2,178 (2,056)."
-
the announcement of a new Phase 3 trial in 2L+ endometrial cancer by end of year is very promising -in addition to the believe that it will also work in non-small cell lung cancer with patients who have EGFR mutations (with patients currently
enrolling in that cohort) -
Jan on GEN1042 -I can tell you that not only we, but also Biontech is very excited about what we have seen up to now with 1042 -- great potential for combining 1042 with different ADCs -- we'll need a bit more data to get a better feeling for durability, but a high level of excitement.
burde der ikke være basis for ca. 5% op USA gik 4,24% frem og med et muligt aktie tilbagekøb så vi håber 
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind